BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...
BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...
BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23% For WtKRAS
BioAtla 在 IASLC 2024 上展示了有关突变 KRAS 基因型和接受 Mecbotamab Vedotin（一种 CAb-AXL-ADC）治疗的晚期 NSCLC 患者临床结果的数据；对于表达 MKRAS 的 NSCLC 患者，1 年的生存率为 58%，而 WtKRAS 的患者为 23%。
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
与接受 Mec-V 治疗的野生型 KRAS (wtKRAS) 治疗无反应的非小细胞肺癌患者相比，接受 Mec-V 治疗的突变 KRAS (mKRAS) 患者的中位总体生存率 (OS) 得到了改善。
One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS
对于表达 mKRAS 的 NSCLC 患者，1 年的生存率为 58%，而 wtKRAS 患者为 23%。
Mec-V antitumor activity observed across 9 different mKRAS variants
Mec-V 在 9 种不同的 mKRAS 变体中观察到了抗肿瘤活性。
Strong association of AXL expression by mKRAS NSCLC confirmed
mKRAS NSCLC AXL 表达的强相关性得到确认。
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, presented a poster entitled "Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC" at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting on December 14, 2024.
加利福尼亚州圣地亚哥，2024 年 12 月 16 日（全球新闻通讯）-- BioAtla, Inc.（纳斯达克：BCAB）是一家专注于开发有条件活性生物（CAB）抗体治疗用于实体瘤治疗的全球临床阶段生物技术公司，于 2024 年 12 月 14 日在 IASLC 2024 热点基础与转化科学会议上展示了题为 "突变 KRAS 基因型和接受 Mecbotamab Vedotin（一种 CAb-AXL-ADC）治疗的晚期 NSCLC 患者临床结果的特征" 的海报。